Logo

ELAB

PMGC Holdings Inc.

ELAB

PMGC Holdings Inc. • NASDAQ
$5.31 ▲ 0.57% (+0.03)
Market Cap $2.25 M
52w High $99.96
52w Low $4.29
Dividend Yield 0%
P/E 0.01
Volume 5.79K
Outstanding Shares 424.23K

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $285.948K ▲ $2.237M ▲ $-2.594M ▼ -907.27% ▼ $0 ▲ $-2.384M ▼
Q2-2025 $0 $1.014M ▼ $-562.355K ▲ 0% $-1.58 ▲ $-579.471K ▲
Q1-2025 $0 ▲ $1.186M ▲ $-1.569M ▲ 0% ▼ $-10.325 ▲ $-1.555M ▼
Q4-2024 $-1.748M ▼ $-2.1M ▼ $-1.935M ▼ 110.71% ▲ $-134.155 ▲ $330.041K ▲
Q3-2024 $527.478K $1.313M $-1.501M -284.61% $-333.2 $-850.239K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $7.701M ▲ $14.938M ▲ $6.447M ▲ $8.491M ▼
Q2-2025 $6.307M ▲ $9.375M ▲ $326.301K ▼ $9.049M ▲
Q1-2025 $5.922M ▲ $8.889M ▼ $760.268K ▼ $8.129M ▲
Q4-2024 $3.984M ▼ $8.993M ▼ $2.334M ▼ $6.66M ▼
Q3-2024 $6.426M $11.205M $2.65M $8.555M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-2.616M ▼ $-1.49M ▼ $-2.198M ▼ $5.706M ▲ $2.018M ▲ $-1.586M ▼
Q2-2025 $-562.355K ▲ $-1.346M ▲ $196.84K ▲ $1.468M ▼ $318.194K ▼ $-1.352M ▼
Q1-2025 $-1.608M ▲ $-1.347M ▲ $-215.319K ▲ $2.943M ▲ $1.38M ▲ $-1.347M ▲
Q4-2024 $-1.935M ▼ $-2.001M ▼ $-439.084K ▼ $0 ▼ $-2.441M ▼ $-2.301M ▼
Q3-2024 $-1.501M $-381.678K $-50K $6.758M $6.326M $-381.68K

Five-Year Company Overview

Income Statement

Income Statement ELAB is essentially pre‑revenue in the historical data you’ve provided. There is no meaningful sales base yet, so the income statement is driven almost entirely by costs rather than business activity. The company is running at a loss, which is normal for an early‑stage biotech and roll‑up platform, but it means results are more about funding development and corporate setup than about operating performance. The unusual swings in per‑share figures look heavily affected by changes in share count and reverse splits rather than by underlying business fundamentals.

Balance Sheet

Balance Sheet The balance sheet shown is extremely light: only a small pool of assets, very little recorded equity, and no debt in the data provided. This suggests a thin financial cushion and a high dependence on raising capital or bringing in cash‑generating acquisitions to grow. The absence of reported cash is striking and may reflect timing, data gaps, or a structure where most operating assets sit in subsidiaries not yet reflected here. Either way, the current balance sheet does not yet show the scale or diversification the strategy aspires to.

Cash Flow

Cash Flow Reported cash flows are modestly negative, reflecting money going out to cover operations and development without any offsetting inflow from a mature business. There is no visible investment in physical assets in this snapshot, which fits a model that is still organizing itself rather than building out heavy infrastructure. Overall, the cash profile is that of a company in build‑out mode: using cash rather than generating it, and likely reliant on outside funding and any acquired subsidiaries to support the strategy.

Competitive Edge

Competitive Edge Competitively, ELAB is trying to build two very different positions at once. On the biotech side, its Northstrive unit focuses on preserving muscle in patients using popular weight‑loss drugs, with a lead engineered probiotic that appears to be early but differentiated and supported by initial clinical safety data and patent protection. That gives it a potential niche in a fast‑growing treatment ecosystem, though it faces all the usual biotech risks: regulatory hurdles, scientific uncertainty, and future competition from larger companies. On the manufacturing side, it is pursuing a roll‑up of U.S. precision machining and related firms serving aerospace and defense. This segment competes in a fragmented but tough market where relationships, quality, and execution matter more than flashy technology. The combined structure—biotech plus manufacturing—is unusual, and the eventual competitive strength will depend on how well management can integrate acquisitions while still advancing the drug pipeline.

Innovation and R&D

Innovation and R&D Innovation is the clear focal point of the biotech arm. The lead candidate, an engineered probiotic aimed at blocking muscle‑inhibiting pathways, is a novel approach to an increasingly important side effect of rapid weight loss. A follow‑on candidate targeting multiple pathways and the use of AI‑driven discovery tools show an intent to build a broader pipeline, not just a single product. The company’s legacy in exosome‑based skincare shows a history of working with advanced biological technologies, even though that business has been spun out. Overall, the R&D story is ambitious and science‑heavy, but still early, with key value drivers residing in future clinical trial outcomes and regulatory interactions rather than in current commercial traction.

Summary

ELAB is in the “story‑building” phase rather than the “steady‑results” phase. Financially, it remains pre‑revenue with a very lean balance sheet and cash flowing out to fund operations, which is typical but leaves limited margin for error. Strategically, it is unusual: combining a high‑risk, high‑reward biotech pipeline aimed at muscle preservation in the GLP‑1 era with a more traditional, cash‑flow‑oriented roll‑up of manufacturing businesses in aerospace and defense. The opportunity lies in turning these two tracks into a self‑reinforcing system where stable industrial earnings help fund long‑duration drug development. The main risks are execution complexity, regulatory and scientific uncertainty, integration of acquisitions, and the need for ongoing access to capital until the strategy matures. Anyone following ELAB will likely be focusing less on current financial ratios and more on clinical milestones, acquisition progress, and evidence that the diversified model can actually deliver durable, scalable cash flows over time.

NEWS

October 20, 2025 · 7:30 AM UTC

PMGC Holdings Inc. Announces Over $711,000.00 in Sales Backlog at AGA Precision Systems LLC and Provides Corporate Update

Read more

September 4, 2025 · 9:54 AM UTC

Northstrive Biosciences Announces Completion of Phase II of AI Development Program with YuvaBio Using MitoNova™ Artificial Intelligence (AI) Platform to Develop Therapies for Obesity and Cardiometabolic Diseases

Read more